<DOC>
	<DOCNO>NCT00438269</DOCNO>
	<brief_summary>Infection develop intensive care unit common complication critical illness , notoriously difficult diagnose . A definite diagnosis base reliable test usually possible least two day . It unclear optimal management approach await result diagnostic test . In circumstance , broad spectrum antibiotic start plan adjust result culture available . Observational study show result great antibiotic use , risk superinfection resistance . In circumstance , antibiotic may withhold pending result culture , strategy lead delay therapy culture positive , may associate bad clinical outcome . We undertake randomize pilot study address question : `` In critically ill patient clinician uncertain whether infection may present , potential site infection manage remove change invasive device , policy delay antibiotic treatment culture available reduce risk excessive antibiotic use , without increase risk associate delayed therapy ? '' Recognizing question formally address , approach clinical management widely divergent passionately hold , pilot study test feasibility acceptability undertake large trial sufficient power determine equivalence .</brief_summary>
	<brief_title>Pilot Study Utility Empiric Antibiotic Therapy Suspected ICU-Acquired Infection</brief_title>
	<detailed_description>We randomize critically ill patient hospital least 72 hour , ICU least 24 hour , manifest either temperature &gt; 38.5 degree , temperature &gt; 38.0 degree white cell count &gt; 12,000 , clinician entertain possibility infection diagnosis , either site-specific broad spectrum empiric antibiotic correspond placebo . All patient underwent comprehensive series investigation identify infectious focus , patient full source control , include change central line urinary catheter , change nasogastric orogastric tube . Patients maintain assign study arm seven day , culture data available , time switch culture-guided narrow spectrum therapy</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Cefazolin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>In hospital &gt; 72 hr ICU &gt; 24hrs , Core temperature ≥38.5°C , temperature ≥ 38.0°C WBC &gt; 12,000/mm3 , temperature ≤ 36.0°C WBC &gt; 12,000/mm3 Suspicion infection Age &lt; 18 year Imminent death ( within 24 hr ) withdrawal aggressive therapy Prosthetic heart valve vascular graft Neutropenia ( Absolute neutrophil count &lt; 1000/mm3 ) Received &gt; 16 hour broad spectrum antibiotic last 24 hour ( 3rd gen cephalosporin , fluoroquinolone , carbapenem , antipseudomonal penicillin ) combination therapy History allergic reaction study medication New physical finding consistent infection : Meningeal sign Peritonitis + free air Abdo xray Soft tissue infection / cellulitis Murmur &amp; suspicion endocarditis Newly available ( within past 24 hour ) culture result consistent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Infection</keyword>
	<keyword>Empiric</keyword>
	<keyword>Antibiotics</keyword>
	<keyword>Nosocomial</keyword>
	<keyword>Pyrexia</keyword>
	<keyword>Leukocytosis</keyword>
	<keyword>Resistance</keyword>
</DOC>